Celiprolol
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | C07AB08 (WHO) |
| Pharmacokinetic data | |
| Bioavailability | 30-70% |
| Biological half-life | 5 hours |
| Identifiers | |
|
|
| CAS Number | 56980-93-9 |
| PubChem (CID) | 2663 |
| DrugBank | DB04846  |
| ChemSpider | 2563 |
| UNII | DRB57K47QC |
| KEGG | D07660 |
| ChEMBL | CHEMBL27810 |
| ECHA InfoCard | 100.054.980 |
| Chemical and physical data | |
| Formula | C20H33N3O4 |
| Molar mass | 379.49 g/mol |
| 3D model (Jmol) | Interactive image |
| Chirality | Racemic mixture |
|
|
Celiprolol (brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm) is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.
In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).[1]
References[edit]
- ^ Ong K-T; et al. (2010). "Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial". Lancet. 376 (9751): 1476–1484. doi:10.1016/S0140-6736(10)60960-9. PMID 20825986.
External links[edit]
- Selectol Summary of Product Characteristics (from the IPHA Medicines Compendium)
- Celiprolol data sheet for New Zealand
 |
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
